BSH 2018 | Identifying TP53 disruptions: a diagnostic measure in CLL
Current diagnostic techniques for chronic lymphocytic leukemia (CLL), which include Sanger sequencing and fluorescent in-situ hybridization, can be complex and costly. Here, Anna Schuh, MD, PhD, MRCP, FRCPath, from Oxford University Hospitals, Oxford, UK, presents the case for identifying TP53 genetic disruptions as a diagnostic measure for CLL. Speaking at British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, Dr Schuh impresses the need to modernize the approach and facilities for genetic diagnosis, and the potential of genomic complexity as a biomarker for predicting treatment response in patients, thereby reducing treatment costs and toxicity in patients.
Get great new content delivered to your inboxSign up